{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T04:38:48Z","timestamp":1717389528848},"reference-count":29,"publisher":"Hindawi Limited","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"funder":[{"name":"Shohadaye Tajrish Hospital of Shahid Beheshti University of Medical Sciences, Iran"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Breast Cancer"],"published-print":{"date-parts":[[2013]]},"abstract":"<jats:p><jats:italic>Background<\/jats:italic>. Adding taxanes to anthracycline-based adjuvant chemotherapy has shown significant improvement particularly in node-positive patients, but optimal dose and schedule remain undetermined.<jats:italic>Objectives<\/jats:italic>. This study aimed to assess the feasibility of dose-dense epirubicin and cyclophosphamide followed by docetaxel in node-positive breast cancer.<jats:italic>Methods<\/jats:italic>. All Patients first received 4 cycles of epirubicin (100\u2009mg\/m<jats:sup>2<\/jats:sup>) and cyclophosphamide (600\u2009mg\/m<jats:sup>2<\/jats:sup>) at 2-week interval then followed by docetaxel (100\u2009mg\/m<jats:sup>2<\/jats:sup>) at 2-week interval for 4 cycles, with daily Pegfilgrastim (G-CSF) that was administered in all patients on days 3\u201310 after each cycle of epirubicin and cyclophosphamide infusion.<jats:italic>Results<\/jats:italic>. Fifty-eight patients with axillary lymph node-positive breast cancer were enrolled in the study, of whom 42 (72.4%) completed the regimen. There were two toxicity-related deaths, one patient due to grade 4 febrile neutropenia and the other due to congestive heart failure. Grade 3\/4 neutropenia and febrile neutropenia were 13.8% and 5.1%. The most common grade 3\/4 nonhematological complications were as follows: skin-nail disorders (48.3%), hand-foot syndrome (34.4%), paresthesia (38%), arthralgia (27.5%), and paresis (24.1%).<jats:italic>Conclusions<\/jats:italic>. Dose-dense epirubicin and cyclophosphamide followed by docetaxel with G-CSF support are not feasible, and it is not recommended for further investigation.<\/jats:p>","DOI":"10.1155\/2013\/404396","type":"journal-article","created":{"date-parts":[[2013,9,25]],"date-time":"2013-09-25T18:36:12Z","timestamp":1380134172000},"page":"1-6","source":"Crossref","is-referenced-by-count":7,"title":["Dose-Dense Epirubicin and Cyclophosphamide Followed by Docetaxel as Adjuvant Chemotherapy in Node-Positive Breast Cancer"],"prefix":"10.1155","volume":"2013","author":[{"given":"Hamid Reza","family":"Mirzaei","sequence":"first","affiliation":[{"name":"Department of Radiation & Oncology, Cancer Research Center, Shohadaye-Tajrish Hospital of Shahid Beheshti University of Medical Sciences and Health Services, Tajrish Square, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parisa","family":"Sabet Rasekh","sequence":"additional","affiliation":[{"name":"Department of Radiation & Oncology, Cancer Research Center, Shohadaye-Tajrish Hospital of Shahid Beheshti University of Medical Sciences and Health Services, Tajrish Square, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatemeh","family":"Nasrollahi","sequence":"additional","affiliation":[{"name":"Department of Radiation & Oncology, Cancer Research Center, Shohadaye-Tajrish Hospital of Shahid Beheshti University of Medical Sciences and Health Services, Tajrish Square, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parto","family":"Sabet Rasekh","sequence":"additional","affiliation":[{"name":"Department of Radiation & Oncology, Cancer Research Center, Shohadaye-Tajrish Hospital of Shahid Beheshti University of Medical Sciences and Health Services, Tajrish Square, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahra","family":"Akbari Tirabad","sequence":"additional","affiliation":[{"name":"Department of Radiation & Oncology, Cancer Research Center, Shohadaye-Tajrish Hospital of Shahid Beheshti University of Medical Sciences and Health Services, Tajrish Square, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamid Reza","family":"Moein","sequence":"additional","affiliation":[{"name":"Department of Radiation & Oncology, Cancer Research Center, Shohadaye-Tajrish Hospital of Shahid Beheshti University of Medical Sciences and Health Services, Tajrish Square, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taban","family":"Ghaffari Pour","sequence":"additional","affiliation":[{"name":"Department of Radiation & Oncology, Cancer Research Center, Shohadaye-Tajrish Hospital of Shahid Beheshti University of Medical Sciences and Health Services, Tajrish Square, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parastoo","family":"Hajian","sequence":"additional","affiliation":[{"name":"Department of Radiation & Oncology, Cancer Research Center, Shohadaye-Tajrish Hospital of Shahid Beheshti University of Medical Sciences and Health Services, Tajrish Square, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","reference":[{"issue":"10","key":"1","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1200\/JCO.1998.16.10.3439","volume":"16","year":"1998","journal-title":"Journal of Clinical Oncology"},{"key":"2","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","volume":"365","year":"2005","journal-title":"The Lancet"},{"issue":"4","key":"3","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/bjc.1993.146","volume":"67","year":"1993","journal-title":"British Journal of Cancer"},{"key":"4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.10.517"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043681"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.3916"},{"key":"7","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602179"},{"key":"8","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2226"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.12.005"},{"key":"10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.6.1456"},{"key":"11","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-004-1001-0"},{"key":"12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043681"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(05)70424-1"},{"issue":"8","key":"14","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1200\/JCO.1986.4.8.1162","volume":"4","year":"1986","journal-title":"Journal of Clinical Oncology"},{"key":"15","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3233\/BD-2001-14104","volume":"14","year":"2001","journal-title":"Breast Disease"},{"issue":"1","key":"16","first-page":"163","volume":"70","year":"1986","journal-title":"Cancer Treatment Reports"},{"issue":"24 i","key":"17","first-page":"7067","volume":"48","year":"1988","journal-title":"Cancer Research"},{"key":"18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.09.081"},{"key":"19","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-200207000-00013"},{"issue":"3","key":"20","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2165\/00003495-199753030-00008","volume":"53","year":"1997","journal-title":"Drugs"},{"key":"21","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.3816\/CBC.2003.s.012","volume":"4","year":"2003","journal-title":"Clinical Breast Cancer"},{"key":"22","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl355"},{"key":"23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0707056"},{"key":"24","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604862"},{"key":"26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.040"},{"key":"27","doi-asserted-by":"publisher","DOI":"10.1016\/S0197-2456(00)00115-X"},{"issue":"1","key":"28","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00280-003-0690-0","volume":"53","year":"2004","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"29","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008345432342"},{"key":"30","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi058"}],"container-title":["International Journal of Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/ijbc\/2013\/404396.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/ijbc\/2013\/404396.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/ijbc\/2013\/404396.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,21]],"date-time":"2017-06-21T18:35:00Z","timestamp":1498070100000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.hindawi.com\/journals\/ijbc\/2013\/404396\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":29,"alternative-id":["404396","404396"],"URL":"https:\/\/doi.org\/10.1155\/2013\/404396","relation":{},"ISSN":["2090-3170","2090-3189"],"issn-type":[{"value":"2090-3170","type":"print"},{"value":"2090-3189","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013]]}}}